The SERVE-HF trial is investigating the value of adaptive servo-ventilation (ASV) to improve morbidity and mortality rates in heart failure patients with predominant central sleep apnoea.

The study aims to enroll over 1,200 patients in more than 80 centres in this randomised, controlled international multicentre, controlled, international outcome trial.